Evidence map›Paper›PMID 36201506›Full record

ArticlePloS one2022

A microfluidics-based method for isolation and visualization of cells based on receptor-ligand interactions.

Long Dao, Qingnan Zhao, Jiemiao Hu, Xueqing Xia, Qing Yang, Shulin Li

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Long DaoDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.ORCID 0000-0002-7857-3242
Qingnan ZhaoDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Jiemiao HuDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Xueqing XiaDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Qing YangDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Shulin LiDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.ORCID 0000-0001-5657-4183
The University of Texas MD Anderson Cancer Center · US

Funding

Gene-Product Auto-Targeting to Tumor VesselsR01CA120895 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, SHULIN · 2007 to 2025
$4.8M
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapseR01NS122857 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEIMBERGER, AMY BETH, LI, SHULIN · 2021 to 2025
$2.9M
Fgl-2 targeted therapy for reversing multi-modality immune suppressionR01CA203493 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEIMBERGER, AMY BETH, LI, SHULIN · 2016 to 2020
$1.8M
Develop CTC capture technology for both mesenchymal and non-mesenchymal tumorsR01EB026291 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, SHULIN · 2018 to 2021
$1.4M
NCI NIH HHS R01 CA120895NCI NIH HHS R01 CA203493NIBIB NIH HHS R01 EB026291NINDS NIH HHS R01 NS122857
6 · The paper itself

Abstract

Receptor-ligand binding has been analyzed at the protein level using isothermal titration calorimetry and surface plasmon resonance and at the cellular level using interaction-associated downstream gene induction/suppression. However, no currently available technique can characterize this interaction directly through visualization. In addition, all available assays require a large pool of cells; no assay capable of analyzing receptor-ligand interactions at the single-cell level is publicly available. Here, we describe a new microfluidic chip-based technique for analyzing and visualizing these interactions at the single-cell level. First, a protein is immobilized on a glass slide and a low-flow-rate pump is used to isolate cells that express receptors that bind to the immobilized ligand. Specifically, we demonstrate the efficacy of this technique by immobilizing biotin-conjugated FGL2 on an avidin-coated slide chip and passing a mixture of GFP-labeled wild-type T cells and RFP-labeled FcγRIIB-knockout T cells through the chip. Using automated scanning and counting, we found a large number of GFP+ T cells with binding activity but significantly fewer RFP+ FcγRIIB-knockout T cells. We further isolated T cells expressing a membrane-anchored, tumor-targeted IL-12 based on the receptor's affinity to vimentin to confirm the versatility of our technique. This protocol allows researchers to isolate receptor-expressing cells in about 4 hours for further downstream processing.

Indexed as

AvidinBiotinInterleukin-12LigandsMicrofluidicsVimentinAvidinBiotinInterleukin-12LigandsVimentin

Identifiers

PMID36201506
PMCPMC9536614
OpenAlexW4302761503

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.